MX377293B - Pirrolamidas como inhibidores de la integrina alfa v. - Google Patents

Pirrolamidas como inhibidores de la integrina alfa v.

Info

Publication number
MX377293B
MX377293B MX2019005233A MX2019005233A MX377293B MX 377293 B MX377293 B MX 377293B MX 2019005233 A MX2019005233 A MX 2019005233A MX 2019005233 A MX2019005233 A MX 2019005233A MX 377293 B MX377293 B MX 377293B
Authority
MX
Mexico
Prior art keywords
compounds
inhibitors
pyrrolamides
integrin
alpha
Prior art date
Application number
MX2019005233A
Other languages
English (en)
Other versions
MX2019005233A (es
Inventor
Guohua Zhao
James Mignone
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2019005233A publication Critical patent/MX2019005233A/es
Publication of MX377293B publication Critical patent/MX377293B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I): (ver Fórmula) o estereoisómeros, tautómeros, o sales o solvatos de los mismos farmacéuticamente aceptables, en donde todas las variables son como se definen en la presente. Estos compuestos son inhibidores a integrinas que contienen aV. Esta invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos y métodos para tratar una enfermedad, trastorno, o condición asociada con la desregulación de integrinas que contienen av, tales como fibrosis patológicas, rechazo al transplante, cáncer, osteoporosis, y afecciones inflamatorias, usando los compuestos y composiciones farmacéuticas.
MX2019005233A 2016-11-08 2017-11-07 Pirrolamidas como inhibidores de la integrina alfa v. MX377293B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662418833P 2016-11-08 2016-11-08
PCT/US2017/060392 WO2018089360A1 (en) 2016-11-08 2017-11-07 Pyrrole amides as alpha v integrin inhibitors

Publications (2)

Publication Number Publication Date
MX2019005233A MX2019005233A (es) 2019-08-12
MX377293B true MX377293B (es) 2025-03-07

Family

ID=60409438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005233A MX377293B (es) 2016-11-08 2017-11-07 Pirrolamidas como inhibidores de la integrina alfa v.

Country Status (23)

Country Link
US (1) US10717736B2 (es)
EP (1) EP3538528B1 (es)
JP (1) JP7220653B2 (es)
KR (1) KR102515507B1 (es)
CN (1) CN110139864B (es)
AU (1) AU2017359030A1 (es)
BR (1) BR112019009293A2 (es)
CA (1) CA3042693A1 (es)
CY (1) CY1123893T1 (es)
DK (1) DK3538528T3 (es)
EA (1) EA201991124A1 (es)
ES (1) ES2852351T3 (es)
HR (1) HRP20210228T1 (es)
HU (1) HUE053620T2 (es)
IL (1) IL266469A (es)
LT (1) LT3538528T (es)
MX (1) MX377293B (es)
PL (1) PL3538528T3 (es)
PT (1) PT3538528T (es)
RS (1) RS61453B1 (es)
SI (1) SI3538528T1 (es)
SM (1) SMT202100089T1 (es)
WO (1) WO2018089360A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049068A1 (en) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
TW201819378A (zh) * 2016-11-08 2018-06-01 美商必治妥美雅史谷比公司 作為αｖ整合素抑制劑之含環丁烷及氮雜環丁烷之單及螺環化合物
BR112019012515A2 (pt) 2016-12-29 2019-11-19 Saint Louis University antagonistas de integrina
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
TW201835078A (zh) 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑
WO2020047208A1 (en) * 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
MX2021002181A (es) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibicion de la integrina alfa v beta 6.
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
US20240208968A1 (en) * 2021-03-10 2024-06-27 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
EP1049693A1 (en) * 1997-11-26 2000-11-08 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
IL138677A0 (en) 1998-04-10 2001-10-31 Searle & Co Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
JP2002522540A (ja) 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
AUPP646598A0 (en) 1998-10-12 1998-11-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing alpha-alanine derivative
DE19939981A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
PL355011A1 (en) * 1999-11-08 2004-03-22 Merck & Co, Inc. Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
GB0001447D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
JP4615826B2 (ja) 2001-01-29 2011-01-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
US20040077684A1 (en) 2002-08-16 2004-04-22 Bart De Corte Piperidinyl compounds that selectively bind integrins
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
BRPI0414927A (pt) 2003-10-01 2006-11-07 Merck Patent Ges Mit Beschaenk antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
WO2007141473A1 (en) 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
EP2526095A1 (en) * 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
NZ603789A (en) 2010-05-26 2015-03-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
DK2953948T3 (en) * 2013-02-07 2017-12-18 Scifluor Life Sciences Inc FLUORINATED INTEGRIN ANTAGONISTS
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CN114805342A (zh) 2015-02-19 2022-07-29 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
EP3268369A4 (en) 2015-03-10 2018-08-08 The Regents of The University of California Anti-alphavbeta1 integrin inhibitors and methods of use

Also Published As

Publication number Publication date
CN110139864B (zh) 2022-08-23
RS61453B1 (sr) 2021-03-31
PT3538528T (pt) 2021-02-16
KR102515507B1 (ko) 2023-03-28
HRP20210228T1 (hr) 2021-03-19
US10717736B2 (en) 2020-07-21
AU2017359030A1 (en) 2019-06-20
KR20190076031A (ko) 2019-07-01
CN110139864A (zh) 2019-08-16
IL266469A (en) 2019-07-31
CY1123893T1 (el) 2022-05-27
JP7220653B2 (ja) 2023-02-10
LT3538528T (lt) 2021-03-10
WO2018089360A1 (en) 2018-05-17
JP2020500182A (ja) 2020-01-09
MX2019005233A (es) 2019-08-12
US20190256512A1 (en) 2019-08-22
CA3042693A1 (en) 2018-05-17
EP3538528A1 (en) 2019-09-18
ES2852351T3 (es) 2021-09-13
DK3538528T3 (da) 2021-02-15
BR112019009293A2 (pt) 2019-07-30
PL3538528T3 (pl) 2021-05-31
SMT202100089T1 (it) 2021-03-15
SI3538528T1 (sl) 2021-03-31
HUE053620T2 (hu) 2021-07-28
EA201991124A1 (ru) 2019-10-31
EP3538528B1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
MX377293B (es) Pirrolamidas como inhibidores de la integrina alfa v.
MX377359B (es) Compuestos mono y espirocíclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v.
MX378565B (es) Derivados de indazol como antagonistas de integrina alfa v.
MY199931A (en) 3-substituted propionic acids as alpha v integrin inhibitors
EA201991121A1 (ru) АЗОЛАМИДЫ И АЗОЛАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV
NZ752250A (en) Compounds, devices, and uses thereof
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
EA201691302A1 (ru) Новые гетероциклические соединения
EA202091063A1 (ru) Мостиковые бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
CY1116692T1 (el) Πυρρολοπυριδινες ως αναστολεις κινασης
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EA202091136A1 (ru) Производные пирролопиразина в качестве ингибиторов альфа-v интегрина
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CO2020005486A2 (es) Compuestos espirocíclicos como moduladores del receptor farnesoide x
MX381224B (es) Potentes moduladores de gamma-secretasa.
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201792109A1 (ru) Конденсированные с тетрагидрофураном производные аминогидротиазина, пригодные для лечения болезни альцгеймера
MX385110B (es) Compuestos de quinoxalina, método para preparar los mismos y uso de los mismos.
PE20171787A1 (es) Sintesis total de trioxacarcina dc-45-a2 y preparacion de analogos de trioxacarcina

Legal Events

Date Code Title Description
FG Grant or registration